{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T08:59:09Z","timestamp":1794473949297,"version":"4.9.1"},"reference-count":178,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T00:00:00Z","timestamp":1718150400000},"content-version":"vor","delay-in-days":11,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82273457"],"award-info":[{"award-number":["82273457"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81501539"],"award-info":[{"award-number":["81501539"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012245","name":"Science and Technology Planning Project of Guangdong Province","doi-asserted-by":"publisher","award":["210715216902829"],"award-info":[{"award-number":["210715216902829"]}],"id":[{"id":"10.13039\/501100012245","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018609","name":"High-level Hospital Construction Project of Guangdong Provincial People's Hospital","doi-asserted-by":"publisher","award":["202003-10"],"award-info":[{"award-number":["202003-10"]}],"id":[{"id":"10.13039\/501100018609","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021171","name":"Basic and Applied Basic Research Foundation of Guangdong Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2021A1515012180"],"award-info":[{"award-number":["2021A1515012180"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2023A1515012762"],"award-info":[{"award-number":["2023A1515012762"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.heliyon.2024.e32998","type":"journal-article","created":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T15:53:09Z","timestamp":1718293989000},"page":"e32998","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Lomitapide repurposing for treatment of malignancies: A promising direction"],"prefix":"10.1016","volume":"10","author":[{"given":"Hua-Tao","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing-Xuan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ze-Xuan","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-Yu","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Kun","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.heliyon.2024.e32998_bib1","first-page":"7","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.heliyon.2024.e32998_bib2","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1002\/ijc.33588","article-title":"Cancer statistics for the year 2020: an overview","volume":"149","author":"Ferlay","year":"2021","journal-title":"Int. J. Cancer"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e32998_bib3","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e32998_bib4","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1158\/1055-9965.EPI-16-0858","article-title":"Global cancer in women: burden and trends","volume":"26","author":"Torre","year":"2017","journal-title":"Cancer Epidemiol. Biomarkers Prev. : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology"},{"issue":"21","key":"10.1016\/j.heliyon.2024.e32998_bib5","doi-asserted-by":"crossref","first-page":"609","DOI":"10.21037\/atm.2019.07.91","article-title":"Concise update on colorectal cancer epidemiology","volume":"7","author":"Mattiuzzi","year":"2019","journal-title":"Ann. Transl. Med."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e32998_bib6","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.tips.2013.03.004","article-title":"Challenges and opportunities of drug repositioning","volume":"34","author":"Novac","year":"2013","journal-title":"Trends Pharmacol. Sci."},{"issue":"3\u20134","key":"10.1016\/j.heliyon.2024.e32998_bib7","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ddstr.2011.10.002","article-title":"Drug repurposing from an academic perspective","volume":"8","author":"Oprea","year":"2011","journal-title":"Drug Discov. Today Ther. Strat."},{"issue":"8","key":"10.1016\/j.heliyon.2024.e32998_bib8","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrd1468","article-title":"Drug repositioning: identifying and developing new uses for existing drugs","volume":"3","author":"Ashburn","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"issue":"10","key":"10.1016\/j.heliyon.2024.e32998_bib9","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1016\/j.drudis.2016.06.021","article-title":"Drug repositioning approaches to parasitic diseases: a medicinal chemistry perspective","volume":"21","author":"Ferreira","year":"2016","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.heliyon.2024.e32998_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctarc.2020.100267","article-title":"The multiple effects of aspirin in prostate cancer patients","volume":"26","author":"Joshi","year":"2021","journal-title":"Cancer treatment and research communications"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e32998_bib11","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.7150\/thno.48698","article-title":"Anti-allergic drug azelastine suppresses colon tumorigenesis by directly targeting ARF1 to inhibit IQGAP1-ERK-Drp1-mediated mitochondrial fission","volume":"11","author":"Hu","year":"2021","journal-title":"Theranostics"},{"issue":"11","key":"10.1016\/j.heliyon.2024.e32998_bib12","first-page":"2397","article-title":"Benzethonium chloride suppresses lung cancer tumorigenesis through inducing p38-mediated cyclin D1 degradation","volume":"9","author":"Huang","year":"2019","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.heliyon.2024.e32998_bib13","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.canlet.2019.02.050","article-title":"Adefovir dipivoxil sensitizes colon cancer cells to vemurafenib by disrupting the KCTD12-CDK1 interaction","volume":"451","author":"Yang","year":"2019","journal-title":"Cancer Lett."},{"key":"10.1016\/j.heliyon.2024.e32998_bib14","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.canlet.2020.05.024","article-title":"Direct targeting of HSP90 with daurisoline destabilizes beta-catenin to suppress lung cancer tumorigenesis","volume":"489","author":"Huang","year":"2020","journal-title":"Cancer Lett."},{"issue":"16","key":"10.1016\/j.heliyon.2024.e32998_bib15","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202000925","article-title":"Direct targeting of CREB1 with imperatorin inhibits TGFbeta2-ERK signaling to suppress esophageal cancer metastasis","volume":"7","author":"Xu","year":"2020","journal-title":"Adv. Sci."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e32998_bib16","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1093\/eurjpc\/zwac028","article-title":"Understanding the efficacy and safety of lomitapide in homozygous familial hypercholesterolaemia","volume":"29","author":"Pirillo","year":"2022","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.heliyon.2024.e32998_bib17","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.canlet.2021.09.010","article-title":"Targeting PP2A with lomitapide suppresses colorectal tumorigenesis through the activation of AMPK\/Beclin1-mediated autophagy","volume":"521","author":"Zuo","year":"2021","journal-title":"Cancer Lett."},{"issue":"28","key":"10.1016\/j.heliyon.2024.e32998_bib18","doi-asserted-by":"crossref","first-page":"4861","DOI":"10.2174\/092986712803341485","article-title":"New clinical perspectives of hypolipidemic drug therapy in severe hypercholesterolemia","volume":"19","author":"Stefanutti","year":"2012","journal-title":"Curr. Med. Chem."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e32998_bib19","doi-asserted-by":"crossref","first-page":"368","DOI":"10.5551\/jat.45708","article-title":"Safety and efficacy of lomitapide in Japanese patients with homozygous familial hypercholesterolemia (HoFH): results from the AEGR-733-301 long-term extension study","volume":"26","author":"Nohara","year":"2019","journal-title":"J Atheroscler Thromb"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e32998_bib20","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1056\/NEJMoa061189","article-title":"Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia","volume":"356","author":"Cuchel","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.heliyon.2024.e32998_bib21","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1743-7075-9-14","article-title":"Multiple functions of microsomal triglyceride transfer protein","volume":"9","author":"Hussain","year":"2012","journal-title":"Nutr. Metab."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e32998_bib22","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1080\/14740338.2019.1602606","article-title":"Review of the long-term safety of lomitapide: a microsomal triglycerides transfer protein inhibitor for treating homozygous familial hypercholesterolemia","volume":"18","author":"Khoury","year":"2019","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.heliyon.2024.e32998_bib23","unstructured":"Drug Information Handbook2016-2017 - 25th edition."},{"key":"10.1016\/j.heliyon.2024.e32998_bib24","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2147\/CE.S174169","article-title":"Lomitapide: a review of its clinical use, efficacy, and tolerability","volume":"14","author":"Alonso","year":"2019","journal-title":"Core Evid."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e32998_bib25","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s40256-013-0030-7","article-title":"Lomitapide: a review of its use in adults with homozygous familial hypercholesterolemia","volume":"13","author":"Perry","year":"2013","journal-title":"Am. J. Cardiovasc. Drugs : drugs, devices, and other interventions"},{"issue":"9","key":"10.1016\/j.heliyon.2024.e32998_bib26","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1161\/CIRCULATIONAHA.113.001292","article-title":"Lomitapide and mipomersen: two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia","volume":"129","author":"Rader","year":"2014","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e32998_bib27","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1161\/CIRCULATIONAHA.117.028208","article-title":"Long-term efficacy and safety of the microsomal triglyceride transfer protein inhibitor lomitapide in patients with homozygous familial hypercholesterolemia","volume":"136","author":"Blom","year":"2017","journal-title":"Circulation"},{"issue":"9860","key":"10.1016\/j.heliyon.2024.e32998_bib28","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(12)61731-0","article-title":"Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study","volume":"381","author":"Cuchel","year":"2013","journal-title":"Lancet (London, England)"},{"issue":"suppl_3","key":"10.1016\/j.heliyon.2024.e32998_bib29","doi-asserted-by":"crossref","first-page":"A12450","DOI":"10.1161\/circ.132.suppl_3.12450","article-title":"Abstract 12450: long-term efficacy and safety of lomitapide for the treatment of homozygous familial hypercholesterolemia: results of the phase 3 extension trial","volume":"132","author":"Blom","year":"2015","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.heliyon.2024.e32998_bib30","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1194\/jlr.M300094-JLR200","article-title":"CP-346086: an MTP inhibitor that lowers plasma cholesterol and triglycerides in experimental animals and in humans","volume":"44","author":"Chandler","year":"2003","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.heliyon.2024.e32998_bib31","series-title":"Cambridge, MA, Aegerion Pharmaceuticals","year":"2020"},{"issue":"10","key":"10.1016\/j.heliyon.2024.e32998_bib32","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/j.numecd.2014.05.009","article-title":"Resistance and intolerance to statins","volume":"24","author":"Reiner","year":"2014","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e32998_bib33","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1517\/14622416.2.1.51","article-title":"ABC drug transporters: hereditary polymorphisms and pharmacological impact in MDR1, MRP1 and MRP2","volume":"2","author":"Kerb","year":"2001","journal-title":"Pharmacogenomics"},{"issue":"12","key":"10.1016\/j.heliyon.2024.e32998_bib34","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1111\/cns.13961","article-title":"Lomitapide ameliorates middle cerebral artery occlusion-induced cerebral ischemia\/reperfusion injury by promoting neuronal autophagy and inhibiting microglial migration","volume":"28","author":"Zheng","year":"2022","journal-title":"CNS Neurosci. Ther."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e32998_bib35","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/s12866-022-02535-9","article-title":"Antibacterial activities and action mode of anti-hyperlipidemic lomitapide against Staphylococcus aureus","volume":"22","author":"Zhang","year":"2022","journal-title":"BMC Microbiol."},{"issue":"7","key":"10.1016\/j.heliyon.2024.e32998_bib36","doi-asserted-by":"crossref","DOI":"10.3390\/molecules25071571","article-title":"Lapatinib, nilotinib and lomitapide inhibit haemozoin formation in malaria parasites","volume":"25","author":"de Sousa","year":"2020","journal-title":"Molecules"},{"issue":"67","key":"10.1016\/j.heliyon.2024.e32998_bib37","doi-asserted-by":"crossref","first-page":"40867","DOI":"10.1039\/D0RA09010G","article-title":"Accelerating the repurposing of FDA-approved drugs against coronavirus disease-19 (COVID-19)","volume":"10","author":"De Vita","year":"2020","journal-title":"RSC advances"},{"key":"10.1016\/j.heliyon.2024.e32998_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.imu.2020.100451","article-title":"Leaving no stone unturned: allosteric targeting of SARS-CoV-2 spike protein at putative druggable sites disrupts human angiotensin-converting enzyme interactions at the receptor binding domain","volume":"21","author":"Olotu","year":"2020","journal-title":"Inform. Med. Unlocked"},{"issue":"7","key":"10.1016\/j.heliyon.2024.e32998_bib39","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/s41419-022-05039-6","article-title":"Lomitapide, a cholesterol-lowering drug, is an anticancer agent that induces autophagic cell death via inhibiting mTOR","volume":"13","author":"Lee","year":"2022","journal-title":"Cell Death Dis."},{"issue":"0 3","key":"10.1016\/j.heliyon.2024.e32998_bib40","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.mce.2015.09.035","article-title":"Endocrine resistance in breast cancer--An overview and update","volume":"418","author":"Clarke","year":"2015","journal-title":"Mol. Cell. Endocrinol."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e32998_bib41","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1073\/pnas.1323719111","article-title":"Differential expression of estrogen receptor alpha, beta1, and beta2 in lobular and ductal breast cancer","volume":"111","author":"Huang","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e32998_bib42","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1677\/ERC-07-0213","article-title":"Downregulation of Aurora-A overrides estrogen-mediated growth and chemoresistance in breast cancer cells","volume":"15","author":"Lee","year":"2008","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.heliyon.2024.e32998_bib43","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/bs.pmch.2021.01.004","article-title":"Use of molecular docking computational tools in drug discovery","volume":"60","author":"Stanzione","year":"2021","journal-title":"Prog. Med. Chem."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e32998_bib44","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/0022-2836(82)90153-X","article-title":"A geometric approach to macromolecule-ligand interactions","volume":"161","author":"Kuntz","year":"1982","journal-title":"J. Mol. Biol."},{"issue":"24","key":"10.1016\/j.heliyon.2024.e32998_bib45","doi-asserted-by":"crossref","first-page":"8461","DOI":"10.1021\/jm101020z","article-title":"Quo vadis, virtual screening? A comprehensive survey of prospective applications","volume":"53","author":"Ripphausen","year":"2010","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e32998_bib46","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1172\/JCI9083","article-title":"Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia","volume":"105","author":"Druker","year":"2000","journal-title":"J. Clin. Invest."},{"issue":"6428","key":"10.1016\/j.heliyon.2024.e32998_bib47","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/363418a0","article-title":"Rational design of potent sialidase-based inhibitors of influenza virus replication","volume":"363","author":"von Itzstein","year":"1993","journal-title":"Nature"},{"issue":"24","key":"10.1016\/j.heliyon.2024.e32998_bib48","doi-asserted-by":"crossref","first-page":"3979","DOI":"10.1021\/jm9704098","article-title":"Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease","volume":"40","author":"Kaldor","year":"1997","journal-title":"J. Med. Chem."},{"issue":"9","key":"10.1016\/j.heliyon.2024.e32998_bib49","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1158\/1535-7163.MCT-11-0426","article-title":"Potent, selective inhibitors of fibroblast growth factor receptor define fibroblast growth factor dependence in preclinical cancer models","volume":"10","author":"Squires","year":"2011","journal-title":"Mol Cancer Ther"},{"issue":"5","key":"10.1016\/j.heliyon.2024.e32998_bib50","doi-asserted-by":"crossref","first-page":"321","DOI":"10.6026\/97320630015321","article-title":"Virtual screening of novel compounds as potential ER-alpha inhibitors","volume":"15","author":"TilakVijay","year":"2019","journal-title":"Bioinformation"},{"issue":"5022","key":"10.1016\/j.heliyon.2024.e32998_bib51","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1126\/science.1715094","article-title":"Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast","volume":"253","author":"Heitman","year":"1991","journal-title":"Science"},{"issue":"5417","key":"10.1016\/j.heliyon.2024.e32998_bib52","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1126\/science.284.5417.1161","article-title":"Interaction of RAFT1 with gephyrin required for rapamycin-sensitive signaling","volume":"284","author":"Sabatini","year":"1999","journal-title":"Science"},{"issue":"6483","key":"10.1016\/j.heliyon.2024.e32998_bib53","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/369756a0","article-title":"A mammalian protein targeted by G1-arresting rapamycin-receptor complex","volume":"369","author":"Brown","year":"1994","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e32998_bib54","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/0092-8674(94)90570-3","article-title":"RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs","volume":"78","author":"Sabatini","year":"1994","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e32998_bib55","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1074\/jbc.270.2.815","article-title":"Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells","volume":"270","author":"Sabers","year":"1995","journal-title":"J. Biol. Chem."},{"issue":"16","key":"10.1016\/j.heliyon.2024.e32998_bib56","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1038\/onc.2016.363","article-title":"mTORC1 and mTORC2 in cancer and the tumor microenvironment","volume":"36","author":"Kim","year":"2017","journal-title":"Oncogene"},{"issue":"21","key":"10.1016\/j.heliyon.2024.e32998_bib57","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1101\/gad.835000","article-title":"Regulation of cellular growth by the Drosophila target of rapamycin dTOR","volume":"14","author":"Zhang","year":"2000","journal-title":"Genes Dev."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e32998_bib58","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.neuron.2014.09.034","article-title":"The neurology of mTOR","volume":"84","author":"Lipton","year":"2014","journal-title":"Neuron"},{"issue":"16","key":"10.1016\/j.heliyon.2024.e32998_bib59","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1101\/gad.1212704","article-title":"Upstream and downstream of mTOR","volume":"18","author":"Hay","year":"2004","journal-title":"Genes Dev."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e32998_bib60","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.cell.2009.03.046","article-title":"DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival","volume":"137","author":"Peterson","year":"2009","journal-title":"Cell"},{"issue":"7448","key":"10.1016\/j.heliyon.2024.e32998_bib61","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nature12122","article-title":"mTOR kinase structure, mechanism and regulation","volume":"497","author":"Yang","year":"2013","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e32998_bib62","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0092-8674(02)00833-4","article-title":"Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action","volume":"110","author":"Hara","year":"2002","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e32998_bib63","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0092-8674(02)00808-5","article-title":"mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery","volume":"110","author":"Kim","year":"2002","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e32998_bib64","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S1097-2765(03)00114-X","article-title":"GbetaL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR","volume":"11","author":"Kim","year":"2003","journal-title":"Mol Cell"},{"issue":"14","key":"10.1016\/j.heliyon.2024.e32998_bib65","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/j.cub.2004.06.054","article-title":"Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton","volume":"14","author":"Sarbassov","year":"2004","journal-title":"Curr. Biol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e32998_bib66","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.cell.2006.08.033","article-title":"SIN1\/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity","volume":"127","author":"Jacinto","year":"2006","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e32998_bib67","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1042\/BJ20070540","article-title":"Identification of Protor as a novel Rictor-binding component of mTOR complex-2","volume":"405","author":"Pearce","year":"2007","journal-title":"Biochem. J."},{"issue":"10","key":"10.1016\/j.heliyon.2024.e32998_bib68","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1158\/2159-8290.CD-12-0345","article-title":"Cancer cell metabolism: one hallmark, many faces","volume":"2","author":"Cantor","year":"2012","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e32998_bib69","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ccr.2007.05.008","article-title":"Defining the role of mTOR in cancer","volume":"12","author":"Guertin","year":"2007","journal-title":"Cancer Cell"},{"issue":"9","key":"10.1016\/j.heliyon.2024.e32998_bib70","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/nrc1974","article-title":"mTOR and cancer: insights into a complex relationship","volume":"6","author":"Sabatini","year":"2006","journal-title":"Nat. Rev. Cancer"},{"issue":"6","key":"10.1016\/j.heliyon.2024.e32998_bib71","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/nm1052","article-title":"mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways","volume":"10","author":"Majumder","year":"2004","journal-title":"Nat. Med."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e32998_bib72","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.2353\/ajpath.2009.080055","article-title":"PTEN deficiency is fully penetrant for prostate adenocarcinoma in C57BL\/6 mice via mTOR-dependent growth","volume":"174","author":"Blando","year":"2009","journal-title":"Am. J. Pathol."},{"issue":"8","key":"10.1016\/j.heliyon.2024.e32998_bib73","doi-asserted-by":"crossref","first-page":"3287","DOI":"10.1158\/0008-5472.CAN-09-3467","article-title":"Mammalian target of rapamycin activator RHEB is frequently overexpressed in human carcinomas and is critical and sufficient for skin epithelial carcinogenesis","volume":"70","author":"Lu","year":"2010","journal-title":"Cancer Res."},{"issue":"12","key":"10.1016\/j.heliyon.2024.e32998_bib74","doi-asserted-by":"crossref","DOI":"10.3390\/cells8121584","article-title":"Targeting mTOR and metabolism in cancer: lessons and innovations","volume":"8","author":"Magaway","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.heliyon.2024.e32998_bib75","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104609","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors: a 2020 update","volume":"152","author":"Roskoski","year":"2020","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.heliyon.2024.e32998_bib76","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s13578-020-00396-1","article-title":"mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges","volume":"10","author":"Zou","year":"2020","journal-title":"Cell Biosci."},{"issue":"24","key":"10.1016\/j.heliyon.2024.e32998_bib77","doi-asserted-by":"crossref","first-page":"6468","DOI":"10.1158\/0008-5472.CAN-12-2395","article-title":"eIF4E\/4E-BP ratio predicts the efficacy of mTOR targeted therapies","volume":"72","author":"Alain","year":"2012","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e32998_bib78","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.cmet.2014.01.001","article-title":"Rapamycin: one drug, many effects","volume":"19","author":"Li","year":"2014","journal-title":"Cell Metab."},{"issue":"16","key":"10.1016\/j.heliyon.2024.e32998_bib79","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1111\/bph.12749","article-title":"Therapeutic targeting of the mTOR-signalling pathway in cancer: benefits and limitations","volume":"171","author":"Moschetta","year":"2014","journal-title":"Br. J. Pharmacol."},{"issue":"Pt 4","key":"10.1016\/j.heliyon.2024.e32998_bib80","first-page":"788","article-title":"Adaptation to mTOR kinase inhibitors by amplification of eIF4E to maintain cap-dependent translation","volume":"127","author":"Cope","year":"2014","journal-title":"J. Cell Sci."},{"issue":"45","key":"10.1016\/j.heliyon.2024.e32998_bib81","doi-asserted-by":"crossref","first-page":"17414","DOI":"10.1073\/pnas.0809136105","article-title":"Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation","volume":"105","author":"Choo","year":"2008","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e32998_bib82","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.cmet.2011.03.009","article-title":"AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice","volume":"13","author":"Li","year":"2011","journal-title":"Cell Metab."},{"issue":"7062","key":"10.1016\/j.heliyon.2024.e32998_bib83","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1038\/nature03967","article-title":"The CREB coactivator TORC2 is a key regulator of fasting glucose metabolism","volume":"437","author":"Koo","year":"2005","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e32998_bib84","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.cell.2011.03.043","article-title":"Class IIa histone deacetylases are hormone-activated regulators of FOXO and mammalian glucose homeostasis","volume":"145","author":"Mihaylova","year":"2011","journal-title":"Cell"},{"issue":"42","key":"10.1016\/j.heliyon.2024.e32998_bib85","doi-asserted-by":"crossref","first-page":"38341","DOI":"10.1074\/jbc.C100316200","article-title":"Regulation of transcription by AMP-activated protein kinase: phosphorylation of p300 blocks its interaction with nuclear receptors","volume":"276","author":"Yang","year":"2001","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e32998_bib86","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1042\/BST20130030","article-title":"The kinase triad, AMPK, mTORC1 and ULK1, maintains energy and nutrient homoeostasis","volume":"41","author":"Dunlop","year":"2013","journal-title":"Biochem. Soc. Trans."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e32998_bib87","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/0014-5793(87)80292-2","article-title":"A common bicyclic protein kinase cascade inactivates the regulatory enzymes of fatty acid and cholesterol biosynthesis","volume":"223","author":"Carling","year":"1987","journal-title":"FEBS Lett."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e32998_bib88","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/j.1432-1033.1988.tb14201.x","article-title":"Identification by amino acid sequencing of three major regulatory phosphorylation sites on rat acetyl-CoA carboxylase","volume":"175","author":"Munday","year":"1988","journal-title":"Eur. J. Biochem."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e32998_bib89","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.cmet.2020.01.015","article-title":"AMPK and TOR: the Yin and Yang of cellular nutrient sensing and growth control","volume":"31","author":"Gonzalez","year":"2020","journal-title":"Cell Metab."},{"key":"10.1016\/j.heliyon.2024.e32998_bib90","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.675599","article-title":"Epigenetic regulation of autophagy beyond the cytoplasm: a review","volume":"9","author":"Shi","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e32998_bib91","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S0092-8674(03)00929-2","article-title":"TSC2 mediates cellular energy response to control cell growth and survival","volume":"115","author":"Inoki","year":"2003","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e32998_bib92","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.molcel.2008.03.003","article-title":"AMPK phosphorylation of raptor mediates a metabolic checkpoint","volume":"30","author":"Gwinn","year":"2008","journal-title":"Mol Cell"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e32998_bib93","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s42255-019-0157-1","article-title":"mTORC1 directly inhibits AMPK to promote cell proliferation under nutrient stress","volume":"2","author":"Ling","year":"2020","journal-title":"Nat. Metab."},{"issue":"17","key":"10.1016\/j.heliyon.2024.e32998_bib94","doi-asserted-by":"crossref","first-page":"5742","DOI":"10.1128\/MCB.21.17.5742-5752.2001","article-title":"Antagonistic controls of autophagy and glycogen accumulation by Snf1p, the yeast homolog of AMP-activated protein kinase, and the cyclin-dependent kinase Pho85p","volume":"21","author":"Wang","year":"2001","journal-title":"Mol. Cell Biol."},{"issue":"46","key":"10.1016\/j.heliyon.2024.e32998_bib95","doi-asserted-by":"crossref","first-page":"34870","DOI":"10.1074\/jbc.M605488200","article-title":"AMP-activated protein kinase and the regulation of autophagic proteolysis","volume":"281","author":"Meley","year":"2006","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e32998_bib96","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.molcel.2006.12.009","article-title":"Control of macroautophagy by calcium, calmodulin-dependent kinase kinase-beta, and Bcl-2","volume":"25","author":"Hoyer-Hansen","year":"2007","journal-title":"Mol Cell"},{"issue":"14","key":"10.1016\/j.heliyon.2024.e32998_bib97","doi-asserted-by":"crossref","first-page":"9187","DOI":"10.1074\/jbc.M708934200","article-title":"Inhibition of GLUT4 translocation by Tbc1d1, a Rab GTPase-activating protein abundant in skeletal muscle, is partially relieved by AMP-activated protein kinase activation","volume":"283","author":"Chavez","year":"2008","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e32998_bib98","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.molcel.2013.01.035","article-title":"AMPK-dependent degradation of TXNIP upon energy stress leads to enhanced glucose uptake via GLUT1","volume":"49","author":"Wu","year":"2013","journal-title":"Mol Cell"},{"issue":"6","key":"10.1016\/j.heliyon.2024.e32998_bib99","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.cmet.2011.05.002","article-title":"Desnutrin\/ATGL is regulated by AMPK and is required for a brown adipose phenotype","volume":"13","author":"Ahmadian","year":"2011","journal-title":"Cell Metab."},{"issue":"12","key":"10.1016\/j.heliyon.2024.e32998_bib100","doi-asserted-by":"crossref","first-page":"4128","DOI":"10.1016\/S0021-9258(17)34693-8","article-title":"Carnitine palmitoyltransferase I. The site of inhibition of hepatic fatty acid oxidation by malonyl-CoA","volume":"253","author":"McGarry","year":"1978","journal-title":"J. Biol. Chem."},{"issue":"9\u201310","key":"10.1016\/j.heliyon.2024.e32998_bib101","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1089\/ars.2006.8.1775","article-title":"Reactive oxygen species-induced activation of the MAP kinase signaling pathways","volume":"8","author":"McCubrey","year":"2006","journal-title":"Antioxid Redox Signal"},{"issue":"22","key":"10.1016\/j.heliyon.2024.e32998_bib102","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1038\/sj.onc.1210421","article-title":"MAP kinase signalling pathways in cancer","volume":"26","author":"Dhillon","year":"2007","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e32998_bib103","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.jmb.2003.08.022","article-title":"Glucose and type 2A protein phosphatase regulate the interaction between catalytic and regulatory subunits of AMP-activated protein kinase","volume":"333","author":"Gimeno-Alcaniz","year":"2003","journal-title":"J. Mol. Biol."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e32998_bib104","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1677\/jme.1.01965","article-title":"Glucose-induced repression of PPARalpha gene expression in pancreatic beta-cells involves PP2A activation and AMPK inactivation","volume":"36","author":"Ravnskjaer","year":"2006","journal-title":"J. Mol. Endocrinol."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e32998_bib105","doi-asserted-by":"crossref","first-page":"C1395","DOI":"10.1152\/ajpcell.00115.2007","article-title":"Ca2+\/calmodulin-dependent protein kinase kinase is involved in AMP-activated protein kinase activation by alpha-lipoic acid in C2C12 myotubes","volume":"293","author":"Shen","year":"2007","journal-title":"Am J Physiol Cell Physiol"},{"issue":"6270","key":"10.1016\/j.heliyon.2024.e32998_bib106","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1126\/science.aab4138","article-title":"Metabolism. AMP-activated protein kinase mediates mitochondrial fission in response to energy stress","volume":"351","author":"Toyama","year":"2016","journal-title":"Science"},{"issue":"44","key":"10.1016\/j.heliyon.2024.e32998_bib107","doi-asserted-by":"crossref","first-page":"17208","DOI":"10.1074\/jbc.RA118.002579","article-title":"Mitochondria-derived ROS activate AMP-activated protein kinase (AMPK) indirectly","volume":"293","author":"Hinchy","year":"2018","journal-title":"J. Biol. Chem."},{"issue":"11","key":"10.1016\/j.heliyon.2024.e32998_bib108","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1038\/nm.2247","article-title":"Autophagy is defective in collagen VI muscular dystrophies, and its reactivation rescues myofiber degeneration","volume":"16","author":"Grumati","year":"2010","journal-title":"Nat. Med."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e32998_bib109","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.cub.2011.11.057","article-title":"A vesicular transport pathway shuttles cargo from mitochondria to lysosomes","volume":"22","author":"Soubannier","year":"2012","journal-title":"Curr. Biol."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e32998_bib110","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1128\/MCB.19.4.2435","article-title":"Mitogen-activated protein kinases: specific messages from ubiquitous messengers","volume":"19","author":"Schaeffer","year":"1999","journal-title":"Mol. Cell Biol."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e32998_bib111","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21031102","article-title":"Targeting MAPK signaling in cancer: mechanisms of drug resistance and sensitivity","volume":"21","author":"Lee","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"9","key":"10.1016\/j.heliyon.2024.e32998_bib112","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/nrd1177","article-title":"p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases","volume":"2","author":"Kumar","year":"2003","journal-title":"Nat. Rev. Drug Discov."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e32998_bib113","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/s41580-020-00322-w","article-title":"Diversity and versatility of p38 kinase signalling in health and disease","volume":"22","author":"Canovas","year":"2021","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e32998_bib114","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S0955-0674(97)80061-0","article-title":"Mitogen-activated protein kinase pathways","volume":"9","author":"Robinson","year":"1997","journal-title":"Curr. Opin. Cell Biol."},{"key":"10.1016\/j.heliyon.2024.e32998_bib115","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0065-230X(08)60765-4","article-title":"Signal transduction through MAP kinase cascades","volume":"74","author":"Lewis","year":"1998","journal-title":"Adv. Cancer Res."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e32998_bib116","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/s13046-020-01671-2","article-title":"RND2 attenuates apoptosis and autophagy in glioblastoma cells by targeting the p38 MAPK signalling pathway","volume":"39","author":"Xu","year":"2020","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.heliyon.2024.e32998_bib117","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14071461","article-title":"Integration of in silico strategies for drug repositioning towards P38alpha mitogen-activated protein kinase (MAPK) at the allosteric site","volume":"14","author":"Suriya","year":"2022","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e32998_bib118","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/cmdc.201700636","article-title":"A comprehensive structural overview of p38alpha mitogen-activated protein kinase in complex with ATP-site and non-ATP-site binders","volume":"13","author":"Astolfi","year":"2018","journal-title":"ChemMedChem"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e32998_bib119","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/nsb770","article-title":"Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site","volume":"9","author":"Pargellis","year":"2002","journal-title":"Nat. Struct. Biol."},{"issue":"8","key":"10.1016\/j.heliyon.2024.e32998_bib120","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1080\/07391102.2018.1475260","article-title":"Human p38alpha mitogen-activated protein kinase in the Asp168-Phe169-Gly170-in (DFG-in) state can bind allosteric inhibitor Doramapimod","volume":"37","author":"Suplatov","year":"2019","journal-title":"J. Biomol. Struct. Dyn."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e32998_bib121","doi-asserted-by":"crossref","first-page":"540","DOI":"10.21873\/cgp.20339","article-title":"Disruption of lipid raft microdomains, regulation of CD38, TP53, and MYC signaling, and induction of apoptosis by lomitapide in multiple myeloma cells","volume":"19","author":"Saeed","year":"2022","journal-title":"Cancer genomics & proteomics"},{"issue":"15","key":"10.1016\/j.heliyon.2024.e32998_bib122","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1101\/gad.1110003","article-title":"Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling","volume":"17","author":"Inoki","year":"2003","journal-title":"Genes Dev."},{"issue":"15","key":"10.1016\/j.heliyon.2024.e32998_bib123","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/S0960-9822(03)00506-2","article-title":"Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb","volume":"13","author":"Tee","year":"2003","journal-title":"Curr. Biol."},{"issue":"9","key":"10.1016\/j.heliyon.2024.e32998_bib124","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/ncb839","article-title":"TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling","volume":"4","author":"Inoki","year":"2002","journal-title":"Nat. Cell Biol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e32998_bib125","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S1097-2765(02)00568-3","article-title":"Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase\/akt pathway","volume":"10","author":"Manning","year":"2002","journal-title":"Mol Cell"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e32998_bib126","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.cell.2005.02.031","article-title":"Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis","volume":"121","author":"Ma","year":"2005","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e32998_bib127","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.gendis.2018.05.001","article-title":"Breast cancer development and progression: risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis","volume":"5","author":"Feng","year":"2018","journal-title":"Genes & diseases"},{"issue":"7434","key":"10.1016\/j.heliyon.2024.e32998_bib128","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/nature11745","article-title":"Regulation of mTORC1 by the Rag GTPases is necessary for neonatal autophagy and survival","volume":"493","author":"Efeyan","year":"2013","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.heliyon.2024.e32998_bib129","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.cmet.2010.03.014","article-title":"Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner","volume":"11","author":"Kalender","year":"2010","journal-title":"Cell Metab."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e32998_bib130","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ccr.2004.06.007","article-title":"The LKB1 tumor suppressor negatively regulates mTOR signaling","volume":"6","author":"Shaw","year":"2004","journal-title":"Cancer Cell"},{"issue":"7","key":"10.1016\/j.heliyon.2024.e32998_bib131","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.molimm.2005.05.002","article-title":"Increased association of CD38 with lipid rafts in T cells from patients with systemic lupus erythematosus and in activated normal T cells","volume":"43","author":"Pavon","year":"2006","journal-title":"Mol. Immunol."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e32998_bib132","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/j.bbamem.2007.03.026","article-title":"Use of cyclodextrins to manipulate plasma membrane cholesterol content: evidence, misconceptions and control strategies","volume":"1768","author":"Zidovetzki","year":"2007","journal-title":"Biochim. Biophys. Acta"},{"issue":"5","key":"10.1016\/j.heliyon.2024.e32998_bib133","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2013.15","article-title":"Lipid raft-mediated Akt signaling as a therapeutic target in mantle cell lymphoma","volume":"3","author":"Reis-Sobreiro","year":"2013","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.heliyon.2024.e32998_bib134","first-page":"39","article-title":"Enzymatic functions and structures of CD38 and homologs","volume":"75","author":"Lee","year":"2000","journal-title":"Chem. Immunol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e32998_bib135","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/S0008-8749(03)00025-X","article-title":"CD38 ligation plays a direct role in the induction of IL-1beta, IL-6, and IL-10 secretion in resting human monocytes","volume":"220","author":"Lande","year":"2002","journal-title":"Cell. Immunol."},{"issue":"10","key":"10.1016\/j.heliyon.2024.e32998_bib136","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1002\/mc.22677","article-title":"CD38 enhances the proliferation and inhibits the apoptosis of cervical cancer cells by affecting the mitochondria functions","volume":"56","author":"Liao","year":"2017","journal-title":"Mol. Carcinog."},{"issue":"7","key":"10.1016\/j.heliyon.2024.e32998_bib137","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1517\/13543784.2012.685650","article-title":"Tyrosine kinase inhibitors as potential drugs for B-cell lymphoid malignancies and autoimmune disorders","volume":"21","author":"Robak","year":"2012","journal-title":"Expet Opin. Invest. Drugs"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e32998_bib138","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.lungcan.2009.10.014","article-title":"Lipid raft modulation inhibits NSCLC cell migration through delocalization of the focal adhesion complex","volume":"69","author":"Jeon","year":"2010","journal-title":"Lung Cancer"},{"issue":"18","key":"10.1016\/j.heliyon.2024.e32998_bib139","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.2174\/0929867325666180111100601","article-title":"Beyond the \"lock and key\" paradigm: targeting lipid rafts to induce the selective apoptosis of cancer cells","volume":"25","author":"Alves","year":"2018","journal-title":"Curr. Med. Chem."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e32998_bib140","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1084\/jem.20040213","article-title":"Intracellular triggering of Fas aggregation and recruitment of apoptotic molecules into Fas-enriched rafts in selective tumor cell apoptosis","volume":"200","author":"Gajate","year":"2004","journal-title":"J. Exp. Med."},{"issue":"10","key":"10.1016\/j.heliyon.2024.e32998_bib141","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/s41568-021-00378-6","article-title":"Cancer metabolism: looking forward","volume":"21","author":"Martinez-Reyes","year":"2021","journal-title":"Nat. Rev. Cancer"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e32998_bib142","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.cell.2005.10.024","article-title":"mTOR and S6K1 mediate assembly of the translation preinitiation complex through dynamic protein interchange and ordered phosphorylation events","volume":"123","author":"Holz","year":"2005","journal-title":"Cell"},{"issue":"5322","key":"10.1016\/j.heliyon.2024.e32998_bib143","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1126\/science.277.5322.99","article-title":"Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin","volume":"277","author":"Brunn","year":"1997","journal-title":"Science"},{"issue":"11","key":"10.1016\/j.heliyon.2024.e32998_bib144","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1101\/gad.13.11.1422","article-title":"Regulation of 4E-BP1 phosphorylation: a novel two-step mechanism","volume":"13","author":"Gingras","year":"1999","journal-title":"Genes Dev."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e32998_bib145","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.cmet.2008.07.007","article-title":"SREBP activity is regulated by mTORC1 and contributes to Akt-dependent cell growth","volume":"8","author":"Porstmann","year":"2008","journal-title":"Cell Metab."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e32998_bib146","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.molcel.2010.06.022","article-title":"Activation of a metabolic gene regulatory network downstream of mTOR complex 1","volume":"39","author":"Duvel","year":"2010","journal-title":"Mol Cell"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e32998_bib147","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.cell.2011.06.034","article-title":"mTOR complex 1 regulates lipin 1 localization to control the SREBP pathway","volume":"146","author":"Peterson","year":"2011","journal-title":"Cell"},{"issue":"6274","key":"10.1016\/j.heliyon.2024.e32998_bib148","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1126\/science.aad0489","article-title":"mTORC1 induces purine synthesis through control of the mitochondrial tetrahydrofolate cycle","volume":"351","author":"Ben-Sahra","year":"2016","journal-title":"Science"},{"issue":"17","key":"10.1016\/j.heliyon.2024.e32998_bib149","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1016\/0006-2952(75)90094-5","article-title":"Digitoxin metabolism by rat liver microsomes","volume":"24","author":"Schmoldt","year":"1975","journal-title":"Biochem. Pharmacol."},{"issue":"7182","key":"10.1016\/j.heliyon.2024.e32998_bib150","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1038\/nature06639","article-title":"Autophagy fights disease through cellular self-digestion","volume":"451","author":"Mizushima","year":"2008","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.heliyon.2024.e32998_bib151","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1158\/2159-8290.CD-19-0292","article-title":"Targeting autophagy in cancer: recent advances and future directions","volume":"9","author":"Amaravadi","year":"2019","journal-title":"Cancer Discov."},{"issue":"7","key":"10.1016\/j.heliyon.2024.e32998_bib152","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1091\/mbc.e08-12-1248","article-title":"Nutrient-dependent mTORC1 association with the ULK1-Atg13-FIP200 complex required for autophagy","volume":"20","author":"Hosokawa","year":"2009","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.heliyon.2024.e32998_bib153","doi-asserted-by":"crossref","first-page":"8048","DOI":"10.1038\/ncomms9048","article-title":"Regulation of autophagy by coordinated action of mTORC1 and protein phosphatase 2A","volume":"6","author":"Wong","year":"2015","journal-title":"Nat. Commun."},{"issue":"11","key":"10.1016\/j.heliyon.2024.e32998_bib154","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.15252\/embr.201642565","article-title":"Identification of PPM1D as an essential Ulk1 phosphatase for genotoxic stress-induced autophagy","volume":"17","author":"Torii","year":"2016","journal-title":"EMBO Rep."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e32998_bib155","doi-asserted-by":"crossref","first-page":"903","DOI":"10.4161\/auto.19653","article-title":"MTORC1 functions as a transcriptional regulator of autophagy by preventing nuclear transport of TFEB","volume":"8","author":"Martina","year":"2012","journal-title":"Autophagy"},{"issue":"228","key":"10.1016\/j.heliyon.2024.e32998_bib156","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.2002790","article-title":"The transcription factor TFEB links mTORC1 signaling to transcriptional control of lysosome homeostasis","volume":"5","author":"Roczniak-Ferguson","year":"2012","journal-title":"Sci. Signal."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e32998_bib157","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1038\/emboj.2012.32","article-title":"A lysosome-to-nucleus signalling mechanism senses and regulates the lysosome via mTOR and TFEB","volume":"31","author":"Settembre","year":"2012","journal-title":"Embo j"},{"issue":"6","key":"10.1016\/j.heliyon.2024.e32998_bib158","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.cell.2012.04.026","article-title":"Tumor suppression in the absence of p53-mediated cell-cycle arrest, apoptosis, and senescence","volume":"149","author":"Li","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.heliyon.2024.e32998_bib159","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1478-811X-8-31","article-title":"PARP-1 cleavage fragments: signatures of cell-death proteases in neurodegeneration","volume":"8","author":"Chaitanya","year":"2010","journal-title":"Cell Commun. Signal. : CCS"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e32998_bib160","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1158\/1535-7163.MCT-14-0496","article-title":"The protein phosphatase 2A inhibitor LB100 sensitizes ovarian carcinoma cells to cisplatin-mediated cytotoxicity","volume":"14","author":"Chang","year":"2015","journal-title":"Mol Cancer Ther"},{"issue":"16","key":"10.1016\/j.heliyon.2024.e32998_bib161","doi-asserted-by":"crossref","first-page":"4422","DOI":"10.1158\/1078-0432.CCR-13-0788","article-title":"Inhibition of protein phosphatase 2A radiosensitizes pancreatic cancers by modulating CDC25C\/CDK1 and homologous recombination repair","volume":"19","author":"Wei","year":"2013","journal-title":"Clin. Cancer Res. : an official journal of the American Association for Cancer Research"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e32998_bib162","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41580-021-00404-3","article-title":"Cell cycle control in cancer","volume":"23","author":"Matthews","year":"2022","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e32998_bib163","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.bbagrm.2014.03.013","article-title":"Myc and cell cycle control","volume":"1849","author":"Bretones","year":"2015","journal-title":"Biochim. Biophys. Acta"},{"issue":"6810","key":"10.1016\/j.heliyon.2024.e32998_bib164","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/35042675","article-title":"Surfing the p53 network","volume":"408","author":"Vogelstein","year":"2000","journal-title":"Nature"},{"issue":"13","key":"10.1016\/j.heliyon.2024.e32998_bib165","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1038\/sj.onc.1210823","article-title":"c-Myc depletion inhibits proliferation of human tumor cells at various stages of the cell cycle","volume":"27","author":"Wang","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.heliyon.2024.e32998_bib166","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1146\/annurev.immunol.14.1.483","article-title":"Immunopharmacology of rapamycin","volume":"14","author":"Abraham","year":"1996","journal-title":"Annu. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e32998_bib167","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1128\/MCB.24.1.200-216.2004","article-title":"mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1\/eukaryotic translation initiation factor 4E","volume":"24","author":"Fingar","year":"2004","journal-title":"Mol. Cell Biol."},{"issue":"7","key":"10.1016\/j.heliyon.2024.e32998_bib168","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.tcb.2011.03.007","article-title":"Autophagy and apoptosis: what is the connection?","volume":"21","author":"Gump","year":"2011","journal-title":"Trends Cell Biol."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e32998_bib169","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3858\/emm.2012.44.2.028","article-title":"Why is autophagy important in human diseases?","volume":"44","author":"Jing","year":"2012","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.heliyon.2024.e32998_bib170","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/502676","article-title":"The impact of autophagy on cell death modalities","volume":"2014","author":"Ryter","year":"2014","journal-title":"Int J Cell Biol"},{"key":"10.1016\/j.heliyon.2024.e32998_bib171","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/102735","article-title":"Role of the crosstalk between autophagy and apoptosis in cancer","volume":"2013","author":"Su","year":"2013","journal-title":"J Oncol"},{"issue":"12","key":"10.1016\/j.heliyon.2024.e32998_bib172","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1002\/ijc.23042","article-title":"Augmented expression of programmed death-1 in both neoplastic and non-neoplastic CD4+ T-cells in adult T-cell leukemia\/lymphoma","volume":"121","author":"Shimauchi","year":"2007","journal-title":"Int. J. Cancer"},{"issue":"6","key":"10.1016\/j.heliyon.2024.e32998_bib173","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.immuni.2016.06.001","article-title":"Resistance mechanisms to immune-checkpoint blockade in cancer: tumor-intrinsic and -extrinsic factors","volume":"44","author":"Pitt","year":"2016","journal-title":"Immunity"},{"issue":"6230","key":"10.1016\/j.heliyon.2024.e32998_bib174","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"issue":"26","key":"10.1016\/j.heliyon.2024.e32998_bib175","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e32998_bib176","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13061359","article-title":"Combining mTOR inhibitors and T cell-based immunotherapies in cancer treatment","volume":"13","author":"El Hage","year":"2021","journal-title":"Cancers"},{"issue":"6","key":"10.1016\/j.heliyon.2024.e32998_bib177","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1002\/hep.29360","article-title":"Programmed cell death-1 (PD-1) checkpoint blockade in combination with a mammalian target of rapamycin inhibitor restrains hepatocellular carcinoma growth induced by hepatoma cell-intrinsic PD-1","volume":"66","author":"Li","year":"2017","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.heliyon.2024.e32998_bib178","doi-asserted-by":"crossref","first-page":"540","DOI":"10.21873\/cgp.20339","article-title":"Disruption of lipid raft microdomains, regulation of CD38, TP53, and MYC signaling, and induction of apoptosis by lomitapide in multiple myeloma cells","volume":"19","author":"Saeed","year":"2022","journal-title":"Cancer Genomics Proteomics"}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024090297?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024090297?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T20:36:37Z","timestamp":1790541397000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844024090297"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":178,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S2405844024090297"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e32998","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lomitapide repurposing for treatment of malignancies: A promising direction","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e32998","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e32998"}}